News for OCGN Stock

Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress Ocugen to Present at the 2025 Cell & Gene Meeting on the Med Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Ocugen Announces Positive Opinion of European Medicines Agency’s Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19 Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit Ocugen CEO to Present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Ocugen Provides Business Update with Third Quarter 2024 Financial Results Ocugen Secures $30 Million in Debt Funding Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024 Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa Ocugen to Participate in a Fireside Chat at Chardan’s 8th Annual Genetic Medicines Conference Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication Ocugen Provides Business Update with Second Quarter 2024 Financial Results Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock Ocugen, Inc. Announces Proposed Public Offering of Common Stock Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy Ocugen to Present at BIO International Convention 2024 Ocugen Set to Join Russell 3000® Index Effective June 28, 2024 Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024 Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy Ocugen Provides Business Update with First Quarter 2024 Financial Results Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock Ocugen to Present at May 2024 Investor Conferences Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024 Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy Ocugen Provides Business Update with Certain Financials for the Year Ending 2023 Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023 Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410 Ocugen to Present at Investing in Cures Summit Ocugen Clinical Showcase Webcast Now Available Ocugen Chairman and CEO to present at Abu Dhabi Family Office Summit Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST Ocugen to Present at 2024 BIO CEO & Investor Conference Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024 Ocugen to Present at Pharma Market Research Conference Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board National Philanthropic Trust Welcomes Three Board Members Ocugen Gains FDA Alignment on Key Aspects of OCU400—Modifier Gene Therapy—Pivotal Phase 3 Study Design Ocugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO Mutations Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Ocugen CEO to Present at NobleCon19 – Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease Ocugen Provides Business Update with Third Quarter 2023 Financial Results Ocugen CSO to Participate in 4th Annual Dry AMD Therapeutic Development Summit Ocugen to Host Conference Call on Thursday, November 9 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2023 Financial Results Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials Ocugen to Present at the 2023 Cell & Gene Meeting on the Mesa Ocugen CSO to Participate in 4th Annual Gene Therapy for Ophthalmic Disorders Conference Ocugen to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference Ocugen, Inc. Announces Connie Collingsworth Joins Business Advisory Board Ocugen to Participate in Panel at Cantor Fitzgerald Global Healthcare Conference 2023 Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA) Ocugen to Host Virtual Investor & Analyst Event on September 13, 2023 Ocugen Provides Business Update with Second Quarter 2023 Financial Results Ocugen to Host Conference Call on Tuesday, August 22 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2023 Financial Results Ocugen CEO & CSO to Present at 41st Annual AAPI Convention and Scientific Assembly Ocugen, Inc. Announces Adjournment of Annual Meeting of Shareholders Ocugen, Inc. Announces Business Advisory Board Ocugen, Inc. Announces Pricing of $16.5 Million Public Offering of Common Stock Ocugen, Inc. Announces Proposed Public Offering of Common Stock Ocugen to Present at BIO International Convention 2023 Ocugen Provides Business Update with First Quarter 2023 Financial Results Ocugen to Host Conference Call on Friday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2023 Financial Results Ocugen Announces OCU410ST Receives Orphan Drug Designation for Treatment of ABCA4-Associated Retinopathies Ocugen, Inc. to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor Conference Ocugen to Present at Association for Research in Vision and Ophthalmology 2023 Annual Meeting Ocugen Announces Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis Ocugen to Host Virtual Investor & Analyst Event on April 14, 2023 Ocugen Chief Scientific Officer to Present at 2023 World Vaccine Congress Ocugen Announces FDA Approval for Enrollment of Pediatric Patients in Ongoing OCU400 Phase 1/2 Clinical Trial for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA) Ocugen, Inc. to Participate in Fireside Chat at 35th Annual Roth Conference Ocugen Appoints Quan A. Vu to Chief Financial Officer & Chief Business Officer Ocugen Provides Business Update with Fourth Quarter and Full Year 2022 Financial Results Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1 Clinical Trial Evaluating OCU200 for the Treatment of Diabetic Macular Edema Ocugen to Present at Retinal Vascular Disease Drug Development Summit Ocugen to Host Conference Call on Tuesday, February 28 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2022 Financial Results Ocugen Appoints Quan A. Vu as Chief Business Officer Ocugen, Inc. to Present at 2023 BIO CEO & Investor Conference Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-bridging and Broadening Study: Both Co-primary Endpoints Met Ocugen Announces Phase 3 Confirmatory Clinical Trial Agreement for NeoCart® Ocugen Announces OCU400 Receives Orphan Drug Designations for Retinitis Pigmentosa and Leber Congenital Amaurosis Ocugen, Inc. to Ring the Nasdaq Stock Market Closing Bell Ocugen Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis Ocugen to Present at 3rd Annual Dry AMD Therapeutics Summit Ocugen Provides Business Update & Third Quarter 2022 Financial Results Ocugen to Host Conference Call on Tuesday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2022 Financial Results Ocugen to Host R&D Day in New York City on Tuesday, November 1, 2022 Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2 Ocugen, Inc. to Present at Upcoming Vaccines, Cell & Gene Therapy Conferences Ocugen, Inc. to Present at Chardan’s 6th Annual Genetic Medicines Conference Ocugen Announces Agreement With Washington University in St. Louis for Commercialization of Intranasal COVID-19 Vaccine in U.S., Europe, and Japan Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Ocugen Announces Publication of a Comprehensive Review of BBV152 in Frontiers in Immunology Ocugen CSO to Participate in 3rd Annual Gene Therapy for Ophthalmic Disorders Conference Ocugen, Inc. to Present at H.C. Wainwright 24th Annual Global Investment Conference Ocugen Appoints Robert J. Hopkins, MD, MPH & TM, FACP, FIDSA, as Chief Medical Officer and Promotes Arun Upadhyay, PhD, to Chief Scientific Officer Ocugen CEO to Present at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference Ocugen Provides Business Update & Second Quarter 2022 Financial Results Ocugen To Host Conference Call on Friday, August 5 at 8:30 a.m. ET to Discuss Business Updates and Second Quarter 2022 Financial Results Ocugen Announces Publication of Positive Results of COVID-19 Vaccine Trial for Children 2-18 in The Lancet Infectious Diseases Ocugen Named Among Philadelphia’s ‘2022 Best Places to Work’ Ocugen, Inc. Announces Issuance of U.S. Patent for Treating Retinal Degenerative Diseases Using Gene Therapy Ocugen, Inc. to Present at BIO International Convention 2022 Ocugen Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition Ocugen, Inc. to Present at H.C. Wainwright Global Investment Conference Ocugen Announces FDA Removes Clinical Hold on Phase 2/3 Clinical Trial for COVAXIN™ (BBV152) Ocugen Provides Business Update and First Quarter 2022 Financial Results Ocugen to Host Conference Call on Friday, May 6 at 8:30 a.m. ET to Provide Business Update and Discuss First Quarter 2022 Financial Results Ocugen, Inc. to Present Preclinical Results at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting Ocugen, Inc. Announces Positive DSMB Recommendation for OCU400-101 Clinical Trial Ocugen, Inc. to Present at NobleCon18 Ocugen, Inc. to Commercialize COVAXIN™ in Mexico, Rights Now Encompassing All of North America Ocugen, Inc. Provides Update on its Phase 2/3 Study of COVAXIN™ (BBV152) Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration Ocugen Announces Appointment of Marna C. Whittington, PhD, to Board of Directors Ocugen, Inc. Appoints Jessica Crespo, CPA, to Chief Accounting Officer and Senior Vice President, Finance Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Ocugen, Inc. to Present at the 34th Annual ROTH Conference Ocugen Provides an Update on its COVAXIN™ Pediatric (2-18) Emergency Use Authorization (EUA) Request Ocugen Provides Business Update With Fourth Quarter and Full Year 2021 Financial Results Ocugen, Inc. Announces Pricing of $53.5 Million Public Offering of Common Stock Ocugen, Inc. Announces Proposed Public Offering of Common Stock Ocugen to Host Conference Call on Friday, February 25 at 8:30 a.m. ET to Discuss Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update Ocugen, Inc. Announces U.S. FDA Lifts Clinical Hold on the Submission of Its Investigational New Drug Application for Its COVID-19 Vaccine Candidate COVAXIN™ (BBV152) Ocugen/Harris Poll Finds Americans Want More COVID-19 Vaccine Options Ocugen, Inc. Signs Letter of Intent to Acquire Vaccine Manufacturing, R&D Hub in Ontario, Canada Ocugen Inc. Announces Nirdosh Jagota, Ph.D. as Senior Vice President, Regulatory Affairs, Compliance & Safety Ocugen, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) COVAXIN™ (BBV152) Booster Shown to Neutralize Both Omicron and Delta Variants of SARS-CoV-2 COVAXIN™ (BBV152) Booster Dose Study Demonstrates Robust Immune Responses and Long-Term Safety Ocugen, Inc. to Present at Upcoming H.C. Wainwright Bioconnect Conference Ocugen Partner, Bharat Biotech, Announces Positive Immunogenicity and Safety Data From COVAXIN™ (BBV152), COVID-19 Candidate Vaccine, in Children 2 – 18 YEARS Ocugen, Inc. Announces Inducement Grants Under  Nasdaq Listing Rule 5635(c)(4) New Data Suggest COVAXIN™ (BBV152) Vaccine Candidate Generates Robust Immune Memory to COVID-19 and Variants of Concern for At Least Six Months After Vaccination Ocugen, Inc. Announces U.S. FDA Acceptance of Investigational New Drug Application to Initiate a Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration Ocugen, Inc. Provides an Update on its Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate COVAXIN™ (BBV152) Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Ocugen Provides Business Update and Third Quarter 2021 Financial Results Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1/2 Clinical Trial Evaluating Gene Therapy Candidate OCU400 (AAV-NR2E3) to Treat Inherited Retinal Degeneration Ocugen, Inc. Announces Submission of Emergency Use Authorization Request to the US FDA for Investigational COVID-19 Vaccine COVAXIN™ (BBV152) for Children Ages 2-18 Years Ocugen to Host Conference Call on Tuesday, November 9 at 8:30 a.m. ET to Discuss Third Quarter 2021 Financial Results and Provide Business Update Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate COVAXIN™ (BBV152) Ocugen Inc. to present pre-clinical data for OCU410 at 2nd Annual Dry AMD Therapeutic Development Conference Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Ocugen, Inc. to Participate in Fireside Chat at the Cantor Virtual Global Healthcare Conference Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Ocugen, Inc. to Present at Upcoming Citi and H.C. Wainwright Investment Conferences Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Ocugen Provides Business Update and Second Quarter 2021 Financial Results Ocugen to Host Conference Call on Friday, August 6 at 8:30 a.m. ET to Discuss Second Quarter 2021 Financial Results and Provide Business Update Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Ocugen, Inc. Announces Initiation of Rolling Submission to Health Canada for COVAXIN™ Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Phase 3 Results Demonstrating 77.8% Protection against Overall Disease Ocugen, Inc. Announces Ken Inchausti as Head, Investor Relations & Communications Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)  Ocugen Inc. Set to Join Russell 3000® Index Ocugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™ Ocugen Inc. Announces Michael Shine as Senior Vice President, Commercial Ocugen to pursue a BLA path in the US for its COVID-19 vaccine candidate Ocugen Expands COVAXIN™ Commercialization Rights to Include Canada Ocugen On Track to Submit Emergency Use Authorization Application to U.S. FDA for its COVID-19 Vaccine Candidate, COVAXIN™ Ocugen Provides Business Update and First Quarter 2021 Financial Results Ocugen Presents New Preclinical OCU200 Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting Ocugen to Host Conference Call on Friday, May 7 at 8:30 a.m. ET to Discuss First Quarter 2021 Financial Results and Provide Business Update Ocugen announces studies showing COVAXIN potentially effective against three key variants of SARS-CoV-2   Ocugen Inc. Announces Closing of $100 Million Registered Direct Offering of Common Stock Priced at a Premium to Market Ocugen Inc. Announces $100 Million Registered Direct Offering of Common Stock Priced at a Premium to Market Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Second Interim Results demonstrating 100% Protection against Severe Disease including Hospitalization Ocugen Inc. Announces John Paul Gabriel as Senior Vice President, Manufacturing and Supply Chain Ocugen Inc. to Participate in a Cantor Fitzgerald Fireside Chat to Discuss COVAXIN COVID-19 Vaccine Development Ocugen Provides Business Update and Full Year 2020 Financial Results Ocugen to Host Conference Call on Thursday, March 18 at 8:30 a.m. ET to Discuss 2020 Financial Results and Provide a Business Update Ocugen Inc. to Present at Upcoming March Investor Conferences Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech shares Phase 3 Interim Results of COVAXIN, Demonstrates Efficacy of 81% European Commission Grants Ocugen Orphan Medicinal Product Designation for Gene Therapy Product Candidate, OCU400, For the Treatment of Both Retinitis Pigmentosa and Leber Congenital Amaurosis Ocugen, Inc. Announces Closing of $23 Million Registered Direct Offering of Common Stock Ocugen Inc. Announces $23 Million Registered Direct Offering of Common Stock Priced at a Premium to Market Ocugen Inc. Announces the Cancellation of Stockholder Meeting Previously Adjourned to 11:00 a.m. Eastern Time on January 13, 2021 Ocugen Inc. Regains Compliance with Nasdaq Bid Price Rule Ocugen Inc. to Present at CTIC, HC Wainwright and Noble Capital Investor Conferences Ocugen Establishes Vaccine Scientific Advisory Board Ocugen Inc. Announces Plan to Adjourn Annual Meeting of Stockholders, Modify Proposal Regarding Increase in Number of Authorized Shares Ocugen and Bharat Biotech to Co-Develop COVAXIN™, a Whole-Virion Inactivated COVID-19 Vaccine, for the US Market Ocugen Inc. Announces Plan to Postpone Annual Meeting of Stockholders CEO Dr. Shankar Musunuri to be Featured as a Panelist at Xconomy’s Xcelerating Life Sciences Virtual Event Discussing The Promise of Cell & Gene Therapies Ocugen Provides Business Update and Third Quarter 2020 Financial Results Ocugen to Present at the GCFF Virtual Conference - Diversified Investing Strategies CEO Dr. Shankar Musunuri to Discuss the Importance of Gene Therapy Strategic Partnerships at 4th Annual Gene Therapy for Rare Disorders Europe Conference Cantor Fitzgerald and Kristen Kluska to Host Zoom Fireside Chat with Ocugen Ocugen Engages Kemwell Biopharma for cGMP Manufacture of OCU200 Ocugen to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Ocugen Granted 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule Ocugen to Present at the LD 500 Virtual Investor Conference Ocugen Provides Business Update and Second Quarter 2020 Financial Results Ocugen to Host Conference Call on Friday, August 14 at 8:30 a.m. ET to Discuss Second Quarter 2020 Financial Results and Provide Business Update Ocugen to Present at World Orphan Drug Congress USA 2020 Conference Ocugen Provides Business Update and First Quarter 2020 Financial Results Ocugen Granted FDA Orphan Drug Designation for OCU400 (AAV-hNR2E3) Gene Therapy for the Treatment of RHO Mutation-Associated Retinal Degenerative Disease Ocugen to Discontinue Phase 3 oGVHD Trial